Oseltamivir

Generic Name: Oseltamivir

Brand Names: Ebilfumin, Tamiflu

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₈N_₂O_₄

CAS Number: 196618-13-0

Unique Ingredient Identifier: 20O93L6F9H

Background: Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B. Oseltamivir exerts its antiviral activity by inhibiting the activity of the viral neuraminidase enzyme found on the surface of the virus, which prevents budding f...

Indication: According to FDA prescribing information, oseltamivir is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours . In particular, this agent is indicated in adults and children including full-term neonates who present with symptoms ...

Associated Conditions: Flu caused by Influenza, Influenza A Virus Infection, Influenza A, Influenza B, Influenza Type B

Associated Therapies: -

Clinical Trials

A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza

Phase 1

Terminated

Conditions: Influenza

Interventions: Drug: Tamiflu

First Posted Date: 2010-01-21

Last Posted Date: 2016-07-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 9

Registration Number: NCT01053663

Open-Label Pharmacokinetic of Oseltamivir in Healthy Obese Thai Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: oseltamivir

First Posted Date: 2010-01-14

Last Posted Date: 2010-10-08

Lead Sponsor: South East Asia Infectious Disease Clinical Research Network

Target Recruit Count: 24

Registration Number: NCT01049763

Locations: 🇹🇭
Mahidol-Oxford Tropical Medicine Research Unit Faculty of Tropical Medicine, Mahidol University Bangkok, Bangkok,, Thailand

Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age

Phase 2

Withdrawn

Conditions: Influenza

Interventions: Drug: Oseltamivir

First Posted Date: 2009-12-23

Last Posted Date: 2014-08-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01037634

A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain

Phase 4

Terminated

Conditions: Influenza

Interventions: Drug: Oseltamivir
Drug: Placebo

First Posted Date: 2009-12-16

Last Posted Date: 2012-10-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 102

Registration Number: NCT01032837

Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU

Phase 2

Terminated

Conditions: Influenza A Virus

Interventions: Drug: Oseltamivir

First Posted Date: 2009-11-09

Last Posted Date: 2011-06-10

Lead Sponsor: University of Manitoba

Target Recruit Count: 59

Registration Number: NCT01010087

Locations: 🇨🇦
Winnipeg Regional Health Authority; Health Sciences Centre, Winnipeg, Manitoba, Canada

A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection

Phase 1

Completed

Conditions: Influenza

Interventions: Drug: Tamiflu

First Posted Date: 2009-10-02

Last Posted Date: 2017-03-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 65

Registration Number: NCT00988325

Locations: 🇩🇪
Onkologische Schwerpunktpraxis Dr. Med. O. Burkhard & B. Reimann, Worms, Germany
🇮🇹
Fondazione Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
🇵🇱
Vitamed, Bydgoszcz, Poland

and more 9 locations

A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection

Phase 3

Terminated

Conditions: Upper Respiratory Tract Infection
Influenza

Interventions: Drug: Zanamivir
Drug: Placebo of Oseltamivir
Drug: Oseltamivir

First Posted Date: 2009-09-18

Last Posted Date: 2011-04-11

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 4

Registration Number: NCT00979667

Locations: 🇭🇰
Sai Ying Pun Jockey Club General Outpatient Clinic, Hong Kong, Hong Kong
🇨🇳
Shau Kei Wan Jockey Club Clinic, Hong Kong, Hong Kong, China
🇭🇰
Fanling Family Medicine Centre, Hong Kong, Hong Kong

A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza

Phase 3

Completed

Conditions: Influenza

Interventions: Drug: Oseltamivir

First Posted Date: 2009-07-30

Last Posted Date: 2016-08-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 37

Registration Number: NCT00949533

Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled Study

Phase 4

Conditions: Influenza

Interventions: Drug: oseltamivir and chinese medicinal herbs
Drug: oseltamivir

First Posted Date: 2009-07-09

Last Posted Date: 2009-11-01

Lead Sponsor: Capital Medical University

Target Recruit Count: 400

Registration Number: NCT00936013

Locations: 🇨🇳
Capital Medical University affiliated Bejing Chaoyang Hospital, Beijing Respiratory Medicine Institute, Beijing, China

Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study

Phase 4

Completed

Conditions: Influenza

Interventions: Drug: chinese medicinal herbs
Drug: oseltamivir and chinese medicinal herbs
Other: blank
Drug: oseltamivir

First Posted Date: 2009-07-08

Last Posted Date: 2009-12-01

Lead Sponsor: Capital Medical University

Target Recruit Count: 102

Registration Number: NCT00935194

Locations: 🇨🇳
Capital Medical University affiliated Beijing Chaoyang Hospital, Beijing Respiratory Medicine Insititute, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy